<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112763">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02077166</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-1123-CA</org_study_id>
    <nct_id>NCT02077166</nct_id>
  </id_info>
  <brief_title>Ibrutinib in Combination With Lenalidomide, With and Without Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Lenalidomide, With and Without Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmacyclics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1b/2 study is designed to assess the safety and efficacy of ibrutinib in
      combination with lenalidomide and rituximab in subjects with relapsed/refractory Diffuse
      Large B-Cell Lymphoma   (DLBCL) not eligible for transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1b: In the dose escalation portion of the study, up to three cohorts may be explored
      and lenalidomide dose escalation will follow the 3+3+3 principle for MTD determination.

      Phase 2: This will be conducted as an international, multicenter, randomized open-label
      study.  Eligible subjects will be randomized in a 1:1 ratio into 2 arms to receive either
      ibrutinib, lenalidomide and rituximab (Treatment Arm A) or ibrutinib and lenalidomide
      (Treatment Arm B).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Phase 1: Maximally tolerated dose (MTD) of lenalidomide in combination with ibrutinib and rituximab, determined by dose-limiting toxicities (DLT) graded using the NCI CTCAE version 4.0</measure>
    <time_frame>Up to 9 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Overall response (OR)</measure>
    <time_frame>Up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Overall response (OR)</measure>
    <time_frame>Up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Duration of response (DOR)</measure>
    <time_frame>Up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Progression free survival (PFS)</measure>
    <time_frame>Up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Overall survival (OS)</measure>
    <time_frame>Up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Complete response (CR)</measure>
    <time_frame>Up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Toxicities by attribute and grade, assessed using NCI CTCAE version</measure>
    <time_frame>Up to 36 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Relapsed Diffuse Large B-Cell Lymphoma</condition>
  <condition>Refractory Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Phase 1: Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2- Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 - Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib PO+ Lenalidomide (PO)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <arm_group_label>Phase 1: Dose Level 1</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 2</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 3</arm_group_label>
    <arm_group_label>Phase 2- Arm A</arm_group_label>
    <arm_group_label>Phase 2 - Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <arm_group_label>Phase 1: Dose Level 1</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 2</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 3</arm_group_label>
    <arm_group_label>Phase 2- Arm A</arm_group_label>
    <arm_group_label>Phase 2 - Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Phase 1: Dose Level 1</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 2</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 3</arm_group_label>
    <arm_group_label>Phase 2- Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed relapsed/ refractory DLBCL

          -  Must have previously received first line treatment regimen

          -  Must be ineligible for high dose therapy/ stem cell transplantation

          -  Measurable disease sites on CT scan (&gt;1.5 cm in longest dimension)

          -  PT/INR &lt;1.5 x ULN and PTT (aPTT) &lt;1.5 x ULN

          -  Men and women ≥18 years of age

          -  ECOG &lt; 2

          -  Adequate hepatic and renal function:

               1. AST or ALT ≤2.5 x ULN

               2. Estimated creatinine clearance (Cockcroft-Gault) &gt;60 mL/min.

          -  Adequate hematologic function:

               1. ANC &gt;1,500 cells/mm3

               2. Plt &gt;75,000 cells/mm3

               3. Hgb &gt;8.0 g/dL

        Exclusion Criteria:

          -  Medically apparent central nervous system lymphoma or leptomeningeal disease

          -  History of allogeneic stem-cell (or other organ) transplantation

          -  Any chemotherapy, external beam radiation therapy, or anticancer antibodies within 2
             weeks

          -  Radio- or toxin-immunoconjugates within 10 weeks

          -  Concurrent enrollment in another therapeutic investigational study or have
             previously taken ibrutinib
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jutta K. Neuenburg, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pharmacyclics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anh Tran</last_name>
    <phone>855-427-8846</phone>
    <email>medinfo@pcyc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khushbu Kaulaskar</last_name>
      <email>kaulaskk@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Radhakrishnan Ramchandren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Boucher</last_name>
      <email>Rebecca.boucher@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Edwin Kingsley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Kdiry</last_name>
      <email>Skdiry@hackensackumc.org</email>
    </contact>
    <investigator>
      <last_name>Andre Goy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Navi</last_name>
      <email>jon3001@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Jia Ruan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid-Ohio Oncology/ Hematology</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathi Toth, RN, OCN</last_name>
      <email>ktoth@zangcenter.com</email>
    </contact>
    <investigator>
      <last_name>Mark Knapp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>February 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
